We are comparing standard immunotherapy treatment with a less frequent dosing schedule for patients with advanced cancer. The goal is to see if the reduced dose is just as effective and to evaluate its impact on quality of life and safety.
We are investigating if dapagliflozin can help prevent the return of atrial fibrillation after cardioversion compared to usual care. This study aims to see how well it works in prolonging the time before atrial fibrillation recurs.
We are studying a new treatment approach for patients with advanced triple-negative breast cancer who have relapsed after prior therapies. This trial aims to see if combining ceralasertib with other medications can improve their response to treatment.
We are studying two treatment combinations to find out which one works better for people with metastatic colorectal cancer. The trial also looks at safety and how treatments affect patients' quality of life.
We are studying a new chemotherapy method to help prevent liver cancer from coming back after surgery. This trial will also look at side effects and how it affects patients' quality of life.
We are studying the effects of a new treatment combining propranolol and pembrolizumab for patients with advanced Angiosarcoma and Undifferentiated Pleomorphic Sarcoma. The goal is to see if this combination improves survival and quality of life.
We are testing a new radioactive treatment for men with prostate cancer. This study aims to evaluate its safety and how well it works.
We are studying whether Denosumab can help prevent breast cancer in women carrying a BRCA1 mutation. This trial compares its effects to a placebo to see if it reduces cancer risk.
We are studying the safety and effectiveness of a new drug, vorasidenib, combined with temozolomide for patients with IDH1- or IDH2-mutant gliomas. This research aims to see if this combination can improve treatment outcomes.
We are studying the effects of a twice-daily dose of Hydroxycarbamide in children with sickle cell disease. This trial aims to evaluate its safety, effectiveness, and how well children tolerate the treatment.
We are studying a new combination therapy for children with cystic fibrosis to evaluate its safety and how well it works. This trial focuses on kids aged 1 to 11 years.
We are evaluating the safety and tolerability of Karonudib in patients with advanced blood cancers like Acute Myeloid Leukemia and Multiple Myeloma. This study aims to find the best dose and understand how well it works with other cancer treatments.
We are testing a new treatment using expanded regulatory T cells for living donor kidney transplant recipients. The goal is to see if this approach is safe and may reduce the need for traditional immunosuppressive medications.
We are exploring how well existing targeted cancer drugs work for patients with rare and hard-to-treat cancers. The study will also look at any serious side effects from these treatments.
We are investigating whether an oral medication called nefopam can reduce morphine use after total knee replacement surgery. This study aims to improve pain management for adults recovering from this procedure.
We are studying if adding trastuzumab and pertuzumab to standard treatment helps improve survival for patients with HER2 positive esophageal adenocarcinoma. This trial involves patients whose cancer can be surgically removed.
We are studying whether ibuprofen can better improve heart health compared to regular pain relief in patients with acute myocarditis. This trial focuses on how these treatments affect heart imaging results after six months.
We are investigating how a full dose of pseudoephedrine affects cycling performance in trained athletes after a tough race simulation. The study also looks at the right dosage and the body's response to it.
We are studying whether early use of levosimendan can improve health outcomes in patients with cardiogenic shock compared to a placebo. The goal is to see if it reduces the need for life support and improves survival rates.
We are studying whether everolimus can help kidney transplant patients with a specific type of rejection maintain kidney function and reduce damage. This trial looks at its effects over six months.